Senhwa Biosciences, Inc. (TPEX:6492)
Taiwan · Delayed Price · Currency is TWD 49.70
-0.90 (-1.78%)
At close: Mar 3, 2026
Senhwa Biosciences Revenue
Senhwa Biosciences had revenue of 330.00K TWD in the quarter ending September 30, 2025, with 32.00% growth. This brings the company's revenue in the last twelve months to 1.08M, up 8.00% year-over-year. In the year 2024, Senhwa Biosciences had annual revenue of 1.00M.
Revenue (ttm)
1.08M
Revenue Growth
+8.00%
P/S Ratio
4,104.19
Revenue / Employee
n/a
Employees
n/a
Market Cap
4.43B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.00M | - | - |
| Dec 31, 2023 | 1.00M | - | - |
| Dec 31, 2022 | 1.00M | 450.00K | 81.82% |
| Dec 31, 2021 | 550.00K | -67.00K | -10.86% |
| Dec 31, 2020 | 617.00K | 317.00K | 105.67% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Panion & Bf Biotech | 2.04B |
| Medigen Biotechnology | 1.59B |
| BioGend Therapeutics | 222.34M |
| Pharmosa Biopharm | 136.72M |
| Intech Biopharm | 113.85M |
| OBI Pharma | 49.29M |
| ACRO Biomedical | 36.50M |
| UnicoCell Biomed | 34.58M |
Senhwa Biosciences News
- 6 months ago - Basal Cell Neoplasms Clinical Trial Pipeline Accelerates as 22+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Benzinga